Next Generation Sequencing (NGS)

Precision medicine, in particular precision oncology, is highly dependent upon genomic characterization of disease and correlation of such features with the targeting drugs. Tumor and disease genomics enabled by innovative changes in technological platforms has been an important part of the recent era of drug development and clinical trials.

Next Generation Sequencing (NGS) is the most widely utilized parallel or deep sequencing technology that has helped the identification of drug targets in the tumor genome and apply such information to interrogating the tumor DNA/RNA. NGS allows simultaneous sequencing of large number of genes for identification of mutations, fusions, and copy number variations. REPROCELL provides NGS services for multiple applications. It provides sequence information of tumor DNA/RNA to patients and physicians to identify druggable targets, and monitoring of response. Less invasive liquid biopsy approach can be used to monitor tumor response to drugs being administered and can be used to change the treatment plan.

REPROCELL NGS services can be used by the pharmaceutical companies for identification and stratification of patients during clinical trials as well use of less invasive liquid biopsy, circulating tumor DNA (ctDNA) for obtaining early data on response.

Where required REPROCELL can also provide confirmatory assessment of mutations and other DNA variations using its in-house capabilities. Our expert Ph.D. level team of molecular biologists and bioinformaticians can work with your needs to design and execute your NGS projects.

NGS Offering

• Biomarker discovery
• Sequence analysis using off the shelf panels
• Custom panel design
• Custom sequence analysis for clinical trials
• ctDNA isolation
• ctDNA sequence analysis
• RNA sequencing (RNAseq)
• Whole exome sequencing